An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH
NCT06129240 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 80
Last updated 2026-02-09
Summary
Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 \& 3 PH.
Conditions
- Pulmonary Hypertension
- Interstitial Lung Disease
Interventions
- DRUG
-
LIQ861
trepostinil inhalation powder in combination with inhaler
Sponsors & Collaborators
-
Liquidia Technologies, Inc.
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-12-28
- Primary Completion
- 2027-07-31
- Completion
- 2028-02-08
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE
NCT02633293 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT07234032 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT07179380 ·Status: RECRUITING ·Phase: PHASE3
-
Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis
NCT00703339 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
NCT07333183 ·Status: RECRUITING ·Phase: PHASE2
-
A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
NCT07285655 ·Status: RECRUITING ·Phase: PHASE3
-
Safety and Tolerability of Inhaled Treprostinil in Adult PH Due to COPD
NCT03012646 ·Status: WITHDRAWN ·Phase: PHASE2
-
Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606
NCT04041648 ·Status: COMPLETED ·Phase: PHASE1
-
Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness
NCT06110403 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease
NCT05176951 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Tracleer (Bosentan) on Pulmonary Arterial Hypertension Related to Eisenmenger Physiology
NCT00317486 ·Status: COMPLETED ·Phase: PHASE4
-
Subcutaneous Treprostinil as a Bridge to Lung Transplantation in Severe Pulmonary Hypertension: A Single-Arm Retrospective Study
NCT06605326 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Observe the Safety, Tolerability, and Efficacy of Remodulin
NCT06603285 ·Status: NOT_YET_RECRUITING
-
Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication
NCT01268553 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Single and Multiple Doses of Different Formulations of a Prostacyclin Receptor Agonist
NCT05427162 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
NCT06649110 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Tezosentan in Pulmonary Arterial Hypertension
NCT01077297 ·Status: TERMINATED ·Phase: PHASE2
-
Hypotonic Treprostinil Subcutaneous Infusion for Control of Treprostinil Related Site Pain
NCT01615627 ·Status: WITHDRAWN ·Phase: PHASE4
-
Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension
NCT00705133 ·Status: COMPLETED ·Phase: PHASE2
-
Tezosentan in Patients With Pulmonary Arterial Hypertension
NCT01094067 ·Status: TERMINATED ·Phase: PHASE2
-
Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
NCT03794583 ·Status: TERMINATED ·Phase: PHASE3
-
Neuromodulation in Patients With Pulmonary Arterial Hypertension
NCT06802380 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)
NCT03496623 ·Status: TERMINATED ·Phase: PHASE3
-
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT05649722 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study of Mosliciguat in PH-ILD
NCT06635850 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2